title: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
abstract: OBJECTIVE
  We compared the pharmacogenetic effects of OATP-C (organic anion transporting polypeptide C) *1a, *1b (A388G), and *5 (T521C) haplotypes on single-dose pharmacokinetics of pravastatin in white subjects.
  
  
  METHODS
  Thirty healthy white male subjects were grouped according to their OATP-C haplotype. Each group contained 10 individuals who were either homozygous or heterozygous carriers of the *1a, *1b, or *5 haplotype. After a single oral dose of 40 mg pravastatin, we analyzed kinetic parameters of pravastatin disposition.
  
  
  RESULTS
  Values for the area under the plasma concentration-time curve from time 0 to 6 hours [AUC(0-6)] in *1a/*1a, *1a/*1b or *1b/*1b, and *1a/*5 individuals were 114.5 +/- 68.6 microg. L(-1). h, 74.8 +/- 35.6 microg. L(-1). h, and 163.0 +/- 64.6 microg. L(-1). h, respectively, with highly significant differences across all 3 study groups (P =.006) and between subjects carrying the *1b and *5 haplotype (P =.002). Strikingly, values of AUC(0-6) from the OATP-C *1b group were more than 60% lower than those derived from carriers of the wild-type OATP-C *1a haplotype, although this difference failed to reach statistical significance. However, the amount of pravastatin excreted into the urine from time 0 to 12 hours [Ae(0-12)] was significantly diminished in the OATP-C *1b haplotype group (1729 +/- 907 microg) compared with *1a wild-type control subjects (2974 +/- 1590 microg) (P =.049).
  
  
  CONCLUSIONS
  There was a significant effect of tested OATP-C variant haplotypes on pravastatin disposition. Whereas *5 expression delayed the hepatocellular uptake of pravastatin, *1b expression seemed to accelerate OATP-C-dependent uptake of the drug.
authors.affiliation: Institute of Clinical Pharmacology, Humboldt University, Berlin, Germany.
authors.forename: Jessica
authors.initials: J
authors.lastname: Mwinyi
authors.forename: Andreas
authors.initials: A
authors.lastname: Johne
authors.forename: Steffen
authors.initials: S
authors.lastname: Bauer
authors.forename: Ivar
authors.initials: I
authors.lastname: Roots
authors.forename: Thomas
authors.initials: T
authors.lastname: Gerloff
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D027381:Liver-Specific Organic Anion Transporter 1 / Q000235:genetics*; D008297:Male; D010597:Pharmacogenetics; D017035:Pravastatin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D017035:Pravastatin